Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]

Guy M Goodwin¹, Scott T Aaronson², Oscar Alvarez³, Robin Carhart-Harris⁴, Jamie Chai-Rees⁵, Megan Croal⁵, Charles DeBattista⁶, Boadie W Dunlop⁷, David Feifel⁸, David J Hellerstein⁹, Muhammad I Husain¹⁰, John R Kelly¹¹, Namik Kirlic¹², Rasmus W Licht¹³, Lindsey Marwood⁵, Thomas D Meyer¹⁴, Sunil Mistry⁵, Ania Nowakowska⁵, Tomáš Páleníček¹⁵, Dimitris Repantis¹⁶, Robert A Schoevers¹⁷, Hollie Simmons⁵, Metten Somers¹⁸, Emma Teoh⁵, Joyce Tsai¹², Mourad Wahba¹⁹, Sam Williams⁵, Allan H Young²⁰, Matthew B Young¹², Sidney Zisook²¹, Ekaterina Malievskaia⁵

Affiliations

¹ Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, UK. Electronic address: guy.goodwin@compasspathways.com.
² The Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt, Baltimore, MD, United States; University of Maryland School of Medicine, Department of Psychiatry, Baltimore, MD, United States.
³ Parc Sanitari Sant Joan de Déu, Barcelona, Spain; Sant Joan de Déu Research Foundation, Barcelona, Spain.
⁴ Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, United States.
⁵ Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, UK.
⁶ Stanford University, Department of Psychiatry and Behavioral Sciences, Stanford, CA, United States.
⁷ Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, Atlanta, GA, United States.
⁸ Kadima Neuropsychiatry Institute, San Diego, CA, United States.
⁹ New York State Psychiatric Institute, Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York City, NY, United States.
¹⁰ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada; Temerty Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, Canada.
¹¹ Trinity Centre for Health Sciences, Department of Psychiatry, Tallaght University Hospital, Dublin, Ireland.
¹² Compass Pathways, Inc. (a subsidiary of Compass Pathways plc), NY, United States.
¹³ Aalborg University Hospital, Department of Psychiatry, Aalborg, Denmark; Aalborg University, Department of Clinical Medicine, Aalborg, Denmark.
¹⁴ Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center, Houston, TX, United States.
¹⁵ The National Institute of Mental Health, Klecany, Czech Republic.
¹⁶ Charité-Universitätsmedizin Berlin, Department of Psychiatry and Neurosciences, Campus Charité Mitte, Germany.
¹⁷ University Medical Centre Groningen, Department of Psychiatry, Groningen, the Netherlands.
¹⁸ University Medical Centre Utrecht Brain Center, Department of Psychiatry, University Medical Center Utrecht, Utrecht, the Netherlands.
¹⁹ Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, UK; Newcastle University, Newcastle upon Tyne, UK.
²⁰ Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, King's College London & South London and Maudsley NHS Foundation Trust, London, UK.
²¹ Department of Psychiatry, University of California San Diego, San Diego, CA, United States.

PMID: 41075579
DOI: 10.1016/j.jad.2025.120352

Published Erratum

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]

Guy M Goodwin et al. J Affect Disord. 2025.

. 2025 Oct 10;393(Pt A):120352.

doi: 10.1016/j.jad.2025.120352. Online ahead of print.

Authors

Affiliations

¹ Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, UK. Electronic address: guy.goodwin@compasspathways.com.
² The Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt, Baltimore, MD, United States; University of Maryland School of Medicine, Department of Psychiatry, Baltimore, MD, United States.
³ Parc Sanitari Sant Joan de Déu, Barcelona, Spain; Sant Joan de Déu Research Foundation, Barcelona, Spain.
⁴ Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, United States.
⁵ Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, UK.
⁶ Stanford University, Department of Psychiatry and Behavioral Sciences, Stanford, CA, United States.
⁷ Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, Atlanta, GA, United States.
⁸ Kadima Neuropsychiatry Institute, San Diego, CA, United States.
⁹ New York State Psychiatric Institute, Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York City, NY, United States.
¹⁰ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada; Temerty Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, Canada.
¹¹ Trinity Centre for Health Sciences, Department of Psychiatry, Tallaght University Hospital, Dublin, Ireland.
¹² Compass Pathways, Inc. (a subsidiary of Compass Pathways plc), NY, United States.
¹³ Aalborg University Hospital, Department of Psychiatry, Aalborg, Denmark; Aalborg University, Department of Clinical Medicine, Aalborg, Denmark.
¹⁴ Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center, Houston, TX, United States.
¹⁵ The National Institute of Mental Health, Klecany, Czech Republic.
¹⁶ Charité-Universitätsmedizin Berlin, Department of Psychiatry and Neurosciences, Campus Charité Mitte, Germany.
¹⁷ University Medical Centre Groningen, Department of Psychiatry, Groningen, the Netherlands.
¹⁸ University Medical Centre Utrecht Brain Center, Department of Psychiatry, University Medical Center Utrecht, Utrecht, the Netherlands.
¹⁹ Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, UK; Newcastle University, Newcastle upon Tyne, UK.
²⁰ Institute of Psychiatry, Psychology and Neuroscience, Department of Psychological Medicine, King's College London & South London and Maudsley NHS Foundation Trust, London, UK.
²¹ Department of Psychiatry, University of California San Diego, San Diego, CA, United States.

PMID: 41075579
DOI: 10.1016/j.jad.2025.120352

No abstract available

PubMed Disclaimer

Erratum for

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
Goodwin GM, Aaronson ST, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Kirlic N, Licht RW, Marwood L, Meyer TD, Mistry S, Nowakowska A, Páleníček T, Repantis D, Schoevers RA, Simmons H, Somers M, Teoh E, Tsai J, Wahba M, Williams S, Young AH, Young MB, Zisook S, Malievskaia E. Goodwin GM, et al. J Affect Disord. 2025 Mar 1;372:523-532. doi: 10.1016/j.jad.2024.12.061. Epub 2024 Dec 18. J Affect Disord. 2025. PMID: 39706482

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]

Affiliations

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources